In an announcement, Grifols SA said that it was signing an exclusive licensing agreement for Aradigm's Pulmaquin and othe proprietary drug concoctions on inhaled ciprofloxacin. The drug regimen is used for the treatment of severe respiratory conditions such as non-cystic fibrosis bronchiectasis among others.
According to Ramon Riera, President Global Commercial for Grifols SA, "Pulmaquin will complement Grifols' existing Prolastin-C business. There is significant overlap between Bronchiecstasis and Alpha1 physicians and patients."
Aside from the drug compound, the Spanish pharmaceutical firm said it may purchase shares in the California based drig company.
In regulatory documents filed. Grifols said it would be investing up to US$65 million as assistance for the development of the dual release ciprofloxacin for inhalation. The drug has completed Phase 2b clinical trials in bronchiectasis patients. It is also set to purchase about US$25.7 million for a 35% stake in Aradigm through purchase of newly issued shares. Aradigm had recently announced a net loss for the first quarter of 2013.
Join the Conversation